A Phase 2 company treating Secondary Progressive Multiple Sclerosis - January 2017
ASX:IIL - Investment thesis
- IIL’s lead drug candidate MIS416 will complete a double blinded placebo controlled Phase 2B trial for secondary progressive multiple sclerosis (SPMS) in April 2017
- There is already strong evidence of safety and likely efficacy from prior trials and a unique 7 year ‘compassionate use’ programme
- There are no drugs currently approved for the safe ongoing treatment of SPMS
- This unmet medical need equates to a potential estimated worldwide annual market of US$7B or more
- There is significant interest from both MS and non-MS Pharma
- IIL expects a corporate transaction late 2017 following release of Phase 2B trial results in Q3/2017
To view Presentation please download PDF attached:
Download this document
